A review on the role of histone deacetylase SIRT6 in high-grade serous ovarian Cancer

Abstract

High-grade serous ovarian cancer (HGSOC) is the most common type of ovarian cancer, accounting for about 70% of all ovarian cancer patients. Despite limited advancements in its treatment over the last decade, few standard therapies are currently available, although the survival rate remains poor. Currently available treatment for HGSOC is employing PARP inhibitors, anti-angiogenic, platinum-based chemotherapy, combination therapy with carboplatin and paclitaxel, etc. Increasing knowledge about the biology and pathways of SIRT6 led to the development of a new promising therapeutic target for HGSOC. SIRT6 can be a novel approach to treat HGSOC by regulating several cellular signaling pathways, including NOTCH3 and Wnt/β-catenin. Down-regulation of SIRT6 is associated with HGSOC and thus, up-regulation of SIRT6 by therapeutic modulators can be efficiently implemented to eradicate HGSOC. This review summarizes the current knowledge about SIRT6, its association with HGSOC, and the mechanisms for targeting SIRT6 to treat high-grade serous ovarian cancer.